nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Lacosamide—CA9—kidney cancer	0.00414	0.396	CrCbGaD
Lisdexamfetamine—Lacosamide—CA2—kidney cancer	0.00372	0.356	CrCbGaD
Lisdexamfetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—ACHE—kidney cancer	0.0025	0.0709	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Dopaminergic Neurogenesis—ALDH1A1—kidney cancer	0.00248	0.0703	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neurotransmitter Clearance In The Synaptic Cleft—BCHE—kidney cancer	0.00218	0.0618	CbGpPWpGaD
Lisdexamfetamine—Lisinopril—ABCB1—kidney cancer	0.00167	0.16	CrCbGaD
Lisdexamfetamine—Decreased appetite—Sorafenib—kidney cancer	0.00161	0.00168	CcSEcCtD
Lisdexamfetamine—Anorexia—Dactinomycin—kidney cancer	0.0016	0.00168	CcSEcCtD
Lisdexamfetamine—Nausea—Pazopanib—kidney cancer	0.0016	0.00168	CcSEcCtD
Lisdexamfetamine—Convulsion—Vincristine—kidney cancer	0.0016	0.00167	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Sorafenib—kidney cancer	0.00159	0.00167	CcSEcCtD
Lisdexamfetamine—Fatigue—Sorafenib—kidney cancer	0.00159	0.00167	CcSEcCtD
Lisdexamfetamine—Hypertension—Vincristine—kidney cancer	0.00159	0.00167	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Paclitaxel—kidney cancer	0.00159	0.00166	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Sunitinib—kidney cancer	0.00158	0.00166	CcSEcCtD
Lisdexamfetamine—Constipation—Sorafenib—kidney cancer	0.00158	0.00165	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Vinblastine—kidney cancer	0.00157	0.00165	CcSEcCtD
Lisdexamfetamine—Eye disorder—Paclitaxel—kidney cancer	0.00157	0.00165	CcSEcCtD
Lisdexamfetamine—Weight increased—Capecitabine—kidney cancer	0.00157	0.00164	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Everolimus—kidney cancer	0.00157	0.00164	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Sunitinib—kidney cancer	0.00156	0.00164	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Paclitaxel—kidney cancer	0.00156	0.00163	CcSEcCtD
Lisdexamfetamine—Weight decreased—Capecitabine—kidney cancer	0.00156	0.00163	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Sunitinib—kidney cancer	0.00154	0.00162	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Sunitinib—kidney cancer	0.00153	0.00161	CcSEcCtD
Lisdexamfetamine—Asthenia—Vinblastine—kidney cancer	0.00153	0.00161	CcSEcCtD
Lisdexamfetamine—Fatigue—Sunitinib—kidney cancer	0.00153	0.00161	CcSEcCtD
Lisdexamfetamine—Depression—Capecitabine—kidney cancer	0.00153	0.0016	CcSEcCtD
Lisdexamfetamine—Asthenia—Everolimus—kidney cancer	0.00153	0.0016	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Capecitabine—kidney cancer	0.00152	0.0016	CcSEcCtD
Lisdexamfetamine—Constipation—Sunitinib—kidney cancer	0.00152	0.00159	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Paclitaxel—kidney cancer	0.00152	0.00159	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Paclitaxel—kidney cancer	0.00151	0.00159	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Capecitabine—kidney cancer	0.00151	0.00159	CcSEcCtD
Lisdexamfetamine—Hypertension—Gemcitabine—kidney cancer	0.00151	0.00158	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Capecitabine—kidney cancer	0.00151	0.00158	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Vincristine—kidney cancer	0.0015	0.00157	CcSEcCtD
Lisdexamfetamine—SLC6A3—Dopaminergic Neurogenesis—ALDH1A1—kidney cancer	0.00148	0.0419	CbGpPWpGaD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.00148	0.00155	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Vincristine—kidney cancer	0.00147	0.00154	CcSEcCtD
Lisdexamfetamine—Asthenia—Erlotinib—kidney cancer	0.00147	0.00154	CcSEcCtD
Lisdexamfetamine—Mental disorder—Paclitaxel—kidney cancer	0.00147	0.00154	CcSEcCtD
Lisdexamfetamine—Urticaria—Sorafenib—kidney cancer	0.00147	0.00154	CcSEcCtD
Lisdexamfetamine—Malnutrition—Paclitaxel—kidney cancer	0.00146	0.00153	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Dactinomycin—kidney cancer	0.00146	0.00153	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Vinblastine—kidney cancer	0.00146	0.00153	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Sorafenib—kidney cancer	0.00146	0.00153	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Everolimus—kidney cancer	0.00146	0.00153	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Vincristine—kidney cancer	0.00145	0.00152	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Capecitabine—kidney cancer	0.00145	0.00152	CcSEcCtD
Lisdexamfetamine—Fatigue—Dactinomycin—kidney cancer	0.00145	0.00152	CcSEcCtD
Lisdexamfetamine—Anorexia—Vincristine—kidney cancer	0.00143	0.0015	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Gemcitabine—kidney cancer	0.00143	0.00149	CcSEcCtD
Lisdexamfetamine—Nervousness—Paclitaxel—kidney cancer	0.00142	0.00149	CcSEcCtD
Lisdexamfetamine—Dizziness—Vinblastine—kidney cancer	0.00141	0.00148	CcSEcCtD
Lisdexamfetamine—Dizziness—Everolimus—kidney cancer	0.00141	0.00147	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Sunitinib—kidney cancer	0.0014	0.00147	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Erlotinib—kidney cancer	0.0014	0.00147	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Gemcitabine—kidney cancer	0.0014	0.00147	CcSEcCtD
Lisdexamfetamine—Skin disorder—Gemcitabine—kidney cancer	0.00138	0.00145	CcSEcCtD
Lisdexamfetamine—Hepatitis—Capecitabine—kidney cancer	0.00138	0.00144	CcSEcCtD
Lisdexamfetamine—Vision blurred—Paclitaxel—kidney cancer	0.00138	0.00144	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Gemcitabine—kidney cancer	0.00138	0.00144	CcSEcCtD
Lisdexamfetamine—Tremor—Paclitaxel—kidney cancer	0.00137	0.00144	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Sorafenib—kidney cancer	0.00136	0.00143	CcSEcCtD
Lisdexamfetamine—Insomnia—Vincristine—kidney cancer	0.00136	0.00142	CcSEcCtD
Lisdexamfetamine—Anorexia—Gemcitabine—kidney cancer	0.00136	0.00142	CcSEcCtD
Lisdexamfetamine—Vomiting—Vinblastine—kidney cancer	0.00136	0.00142	CcSEcCtD
Lisdexamfetamine—Dizziness—Erlotinib—kidney cancer	0.00136	0.00142	CcSEcCtD
Lisdexamfetamine—Vomiting—Everolimus—kidney cancer	0.00135	0.00142	CcSEcCtD
Lisdexamfetamine—Agitation—Paclitaxel—kidney cancer	0.00134	0.00141	CcSEcCtD
Lisdexamfetamine—Rash—Everolimus—kidney cancer	0.00134	0.00141	CcSEcCtD
Lisdexamfetamine—Dermatitis—Everolimus—kidney cancer	0.00134	0.0014	CcSEcCtD
Lisdexamfetamine—Headache—Vinblastine—kidney cancer	0.00134	0.0014	CcSEcCtD
Lisdexamfetamine—Angioedema—Paclitaxel—kidney cancer	0.00134	0.0014	CcSEcCtD
Lisdexamfetamine—Headache—Everolimus—kidney cancer	0.00133	0.0014	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Dactinomycin—kidney cancer	0.00133	0.00139	CcSEcCtD
Lisdexamfetamine—Visual impairment—Capecitabine—kidney cancer	0.00133	0.00139	CcSEcCtD
Lisdexamfetamine—Asthenia—Sorafenib—kidney cancer	0.00132	0.00139	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Doxorubicin—kidney cancer	0.00131	0.00137	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Sunitinib—kidney cancer	0.00131	0.00137	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Vincristine—kidney cancer	0.00131	0.00137	CcSEcCtD
Lisdexamfetamine—Vomiting—Erlotinib—kidney cancer	0.0013	0.00137	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Capecitabine—kidney cancer	0.0013	0.00137	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Vincristine—kidney cancer	0.0013	0.00136	CcSEcCtD
Lisdexamfetamine—Fatigue—Vincristine—kidney cancer	0.0013	0.00136	CcSEcCtD
Lisdexamfetamine—Rash—Erlotinib—kidney cancer	0.00129	0.00136	CcSEcCtD
Lisdexamfetamine—Dermatitis—Erlotinib—kidney cancer	0.00129	0.00135	CcSEcCtD
Lisdexamfetamine—Palpitations—Paclitaxel—kidney cancer	0.00129	0.00135	CcSEcCtD
Lisdexamfetamine—Insomnia—Gemcitabine—kidney cancer	0.00129	0.00135	CcSEcCtD
Lisdexamfetamine—Eye disorder—Capecitabine—kidney cancer	0.00129	0.00135	CcSEcCtD
Lisdexamfetamine—Headache—Erlotinib—kidney cancer	0.00129	0.00135	CcSEcCtD
Lisdexamfetamine—Constipation—Vincristine—kidney cancer	0.00129	0.00135	CcSEcCtD
Lisdexamfetamine—Diplopia—Doxorubicin—kidney cancer	0.00128	0.00135	CcSEcCtD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—LRRK2—kidney cancer	0.00128	0.0364	CbGpPWpGaD
Lisdexamfetamine—Cardiac disorder—Capecitabine—kidney cancer	0.00128	0.00134	CcSEcCtD
Lisdexamfetamine—Asthenia—Sunitinib—kidney cancer	0.00127	0.00134	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Gemcitabine—kidney cancer	0.00127	0.00133	CcSEcCtD
Lisdexamfetamine—Nausea—Vinblastine—kidney cancer	0.00127	0.00133	CcSEcCtD
Lisdexamfetamine—Somnolence—Gemcitabine—kidney cancer	0.00127	0.00133	CcSEcCtD
Lisdexamfetamine—Convulsion—Paclitaxel—kidney cancer	0.00127	0.00133	CcSEcCtD
Lisdexamfetamine—Affect lability—Doxorubicin—kidney cancer	0.00126	0.00133	CcSEcCtD
Lisdexamfetamine—Nausea—Everolimus—kidney cancer	0.00126	0.00132	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Sorafenib—kidney cancer	0.00126	0.00132	CcSEcCtD
Lisdexamfetamine—Hypertension—Paclitaxel—kidney cancer	0.00126	0.00132	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Capecitabine—kidney cancer	0.00125	0.00131	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Capecitabine—kidney cancer	0.00124	0.0013	CcSEcCtD
Lisdexamfetamine—Anxiety—Paclitaxel—kidney cancer	0.00124	0.0013	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Gemcitabine—kidney cancer	0.00124	0.0013	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Dactinomycin—kidney cancer	0.00124	0.0013	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.00124	0.0013	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.00123	0.00129	CcSEcCtD
Lisdexamfetamine—Fatigue—Gemcitabine—kidney cancer	0.00123	0.00129	CcSEcCtD
Lisdexamfetamine—Dizziness—Sorafenib—kidney cancer	0.00122	0.00128	CcSEcCtD
Lisdexamfetamine—Constipation—Gemcitabine—kidney cancer	0.00122	0.00128	CcSEcCtD
Lisdexamfetamine—Nausea—Erlotinib—kidney cancer	0.00122	0.00128	CcSEcCtD
Lisdexamfetamine—Dry mouth—Paclitaxel—kidney cancer	0.00122	0.00128	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Sunitinib—kidney cancer	0.00122	0.00127	CcSEcCtD
Lisdexamfetamine—Mental disorder—Capecitabine—kidney cancer	0.00121	0.00127	CcSEcCtD
Lisdexamfetamine—Asthenia—Dactinomycin—kidney cancer	0.00121	0.00126	CcSEcCtD
Lisdexamfetamine—Malnutrition—Capecitabine—kidney cancer	0.0012	0.00126	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Paclitaxel—kidney cancer	0.00119	0.00125	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Vincristine—kidney cancer	0.00119	0.00124	CcSEcCtD
Lisdexamfetamine—Dizziness—Sunitinib—kidney cancer	0.00117	0.00123	CcSEcCtD
Lisdexamfetamine—Vomiting—Sorafenib—kidney cancer	0.00117	0.00123	CcSEcCtD
Lisdexamfetamine—Abdominal pain upper—Doxorubicin—kidney cancer	0.00117	0.00123	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Paclitaxel—kidney cancer	0.00117	0.00123	CcSEcCtD
Lisdexamfetamine—Tachycardia—Paclitaxel—kidney cancer	0.00116	0.00122	CcSEcCtD
Lisdexamfetamine—Rash—Sorafenib—kidney cancer	0.00116	0.00122	CcSEcCtD
Lisdexamfetamine—Dermatitis—Sorafenib—kidney cancer	0.00116	0.00122	CcSEcCtD
Lisdexamfetamine—Skin disorder—Paclitaxel—kidney cancer	0.00116	0.00121	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Doxorubicin—kidney cancer	0.00116	0.00121	CcSEcCtD
Lisdexamfetamine—Headache—Sorafenib—kidney cancer	0.00116	0.00121	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Paclitaxel—kidney cancer	0.00115	0.00121	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Dactinomycin—kidney cancer	0.00115	0.00121	CcSEcCtD
Lisdexamfetamine—Anorexia—Paclitaxel—kidney cancer	0.00114	0.00119	CcSEcCtD
Lisdexamfetamine—Vision blurred—Capecitabine—kidney cancer	0.00113	0.00119	CcSEcCtD
Lisdexamfetamine—Vomiting—Sunitinib—kidney cancer	0.00113	0.00118	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Gemcitabine—kidney cancer	0.00113	0.00118	CcSEcCtD
Lisdexamfetamine—Tremor—Capecitabine—kidney cancer	0.00112	0.00118	CcSEcCtD
Lisdexamfetamine—Rash—Sunitinib—kidney cancer	0.00112	0.00117	CcSEcCtD
Lisdexamfetamine—Dermatitis—Sunitinib—kidney cancer	0.00112	0.00117	CcSEcCtD
Lisdexamfetamine—Headache—Sunitinib—kidney cancer	0.00111	0.00117	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Vincristine—kidney cancer	0.00111	0.00116	CcSEcCtD
Lisdexamfetamine—Nausea—Sorafenib—kidney cancer	0.0011	0.00115	CcSEcCtD
Lisdexamfetamine—Insomnia—Paclitaxel—kidney cancer	0.00108	0.00113	CcSEcCtD
Lisdexamfetamine—Asthenia—Vincristine—kidney cancer	0.00108	0.00113	CcSEcCtD
Lisdexamfetamine—Vomiting—Dactinomycin—kidney cancer	0.00107	0.00112	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Paclitaxel—kidney cancer	0.00106	0.00112	CcSEcCtD
Lisdexamfetamine—Somnolence—Paclitaxel—kidney cancer	0.00106	0.00111	CcSEcCtD
Lisdexamfetamine—Palpitations—Capecitabine—kidney cancer	0.00106	0.00111	CcSEcCtD
Lisdexamfetamine—Rash—Dactinomycin—kidney cancer	0.00106	0.00111	CcSEcCtD
Lisdexamfetamine—Nausea—Sunitinib—kidney cancer	0.00106	0.00111	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Paclitaxel—kidney cancer	0.00105	0.0011	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Paclitaxel—kidney cancer	0.00104	0.00109	CcSEcCtD
Lisdexamfetamine—Hypertension—Capecitabine—kidney cancer	0.00104	0.00109	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.00103	0.00108	CcSEcCtD
Lisdexamfetamine—Fatigue—Paclitaxel—kidney cancer	0.00103	0.00108	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Vincristine—kidney cancer	0.00103	0.00108	CcSEcCtD
Lisdexamfetamine—Asthenia—Gemcitabine—kidney cancer	0.00102	0.00107	CcSEcCtD
Lisdexamfetamine—Constipation—Paclitaxel—kidney cancer	0.00102	0.00107	CcSEcCtD
Lisdexamfetamine—Anxiety—Capecitabine—kidney cancer	0.00102	0.00107	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.00101	0.00106	CcSEcCtD
Lisdexamfetamine—Weight increased—Doxorubicin—kidney cancer	0.00101	0.00106	CcSEcCtD
Lisdexamfetamine—Weight decreased—Doxorubicin—kidney cancer	0.001	0.00105	CcSEcCtD
Lisdexamfetamine—Dry mouth—Capecitabine—kidney cancer	0.000999	0.00105	CcSEcCtD
Lisdexamfetamine—Nausea—Dactinomycin—kidney cancer	0.000999	0.00105	CcSEcCtD
Lisdexamfetamine—Dizziness—Vincristine—kidney cancer	0.000994	0.00104	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	0.000981	0.00103	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Gemcitabine—kidney cancer	0.000975	0.00102	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Capecitabine—kidney cancer	0.000961	0.00101	CcSEcCtD
Lisdexamfetamine—Tachycardia—Capecitabine—kidney cancer	0.000956	0.001	CcSEcCtD
Lisdexamfetamine—Vomiting—Vincristine—kidney cancer	0.000955	0.001	CcSEcCtD
Lisdexamfetamine—Skin disorder—Capecitabine—kidney cancer	0.000951	0.000997	CcSEcCtD
Lisdexamfetamine—Urticaria—Paclitaxel—kidney cancer	0.000948	0.000994	CcSEcCtD
Lisdexamfetamine—Rash—Vincristine—kidney cancer	0.000948	0.000993	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Capecitabine—kidney cancer	0.000947	0.000992	CcSEcCtD
Lisdexamfetamine—Dermatitis—Vincristine—kidney cancer	0.000947	0.000992	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Paclitaxel—kidney cancer	0.000944	0.000989	CcSEcCtD
Lisdexamfetamine—Headache—Vincristine—kidney cancer	0.000941	0.000987	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Doxorubicin—kidney cancer	0.000936	0.000981	CcSEcCtD
Lisdexamfetamine—Selegiline—ABCB1—kidney cancer	0.000936	0.0894	CrCbGaD
Lisdexamfetamine—Anorexia—Capecitabine—kidney cancer	0.000934	0.000978	CcSEcCtD
Lisdexamfetamine—SLC6A2—Monoamine Transport—ACHE—kidney cancer	0.000931	0.0264	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.00093	0.0264	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—CASP2—kidney cancer	0.000927	0.0263	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Gemcitabine—kidney cancer	0.000906	0.00095	CcSEcCtD
Lisdexamfetamine—Rash—Gemcitabine—kidney cancer	0.000899	0.000942	CcSEcCtD
Lisdexamfetamine—Dermatitis—Gemcitabine—kidney cancer	0.000898	0.000941	CcSEcCtD
Lisdexamfetamine—Headache—Gemcitabine—kidney cancer	0.000893	0.000936	CcSEcCtD
Lisdexamfetamine—Nausea—Vincristine—kidney cancer	0.000893	0.000935	CcSEcCtD
Lisdexamfetamine—Hepatitis—Doxorubicin—kidney cancer	0.000889	0.000931	CcSEcCtD
Lisdexamfetamine—Insomnia—Capecitabine—kidney cancer	0.000886	0.000928	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Paclitaxel—kidney cancer	0.000879	0.000922	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Capecitabine—kidney cancer	0.000873	0.000915	CcSEcCtD
Lisdexamfetamine—SLC6A3—Parkinsons Disease Pathway—APAF1—kidney cancer	0.000872	0.0247	CbGpPWpGaD
Lisdexamfetamine—Dyspepsia—Capecitabine—kidney cancer	0.000862	0.000904	CcSEcCtD
Lisdexamfetamine—Visual impairment—Doxorubicin—kidney cancer	0.000856	0.000898	CcSEcCtD
Lisdexamfetamine—Asthenia—Paclitaxel—kidney cancer	0.000856	0.000897	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Capecitabine—kidney cancer	0.000851	0.000892	CcSEcCtD
Lisdexamfetamine—Nausea—Gemcitabine—kidney cancer	0.000847	0.000887	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000846	0.000886	CcSEcCtD
Lisdexamfetamine—Fatigue—Capecitabine—kidney cancer	0.000844	0.000885	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Doxorubicin—kidney cancer	0.00084	0.000881	CcSEcCtD
Lisdexamfetamine—Constipation—Capecitabine—kidney cancer	0.000838	0.000878	CcSEcCtD
Lisdexamfetamine—Eye disorder—Doxorubicin—kidney cancer	0.000831	0.00087	CcSEcCtD
Lisdexamfetamine—SLC6A3—Monoamine Transport—ACHE—kidney cancer	0.000825	0.0234	CbGpPWpGaD
Lisdexamfetamine—Cardiac disorder—Doxorubicin—kidney cancer	0.000825	0.000864	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Paclitaxel—kidney cancer	0.000817	0.000856	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Doxorubicin—kidney cancer	0.000803	0.000841	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Doxorubicin—kidney cancer	0.000801	0.000839	CcSEcCtD
Lisdexamfetamine—Dizziness—Paclitaxel—kidney cancer	0.000789	0.000827	CcSEcCtD
Lisdexamfetamine—Mental disorder—Doxorubicin—kidney cancer	0.000779	0.000816	CcSEcCtD
Lisdexamfetamine—Urticaria—Capecitabine—kidney cancer	0.000778	0.000815	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Capecitabine—kidney cancer	0.000774	0.000811	CcSEcCtD
Lisdexamfetamine—Malnutrition—Doxorubicin—kidney cancer	0.000774	0.000811	CcSEcCtD
Lisdexamfetamine—Vomiting—Paclitaxel—kidney cancer	0.000759	0.000795	CcSEcCtD
Lisdexamfetamine—Rash—Paclitaxel—kidney cancer	0.000753	0.000789	CcSEcCtD
Lisdexamfetamine—Dermatitis—Paclitaxel—kidney cancer	0.000752	0.000788	CcSEcCtD
Lisdexamfetamine—Nervousness—Doxorubicin—kidney cancer	0.000751	0.000787	CcSEcCtD
Lisdexamfetamine—Headache—Paclitaxel—kidney cancer	0.000748	0.000784	CcSEcCtD
Lisdexamfetamine—Vision blurred—Doxorubicin—kidney cancer	0.000729	0.000764	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Capecitabine—kidney cancer	0.000722	0.000756	CcSEcCtD
Lisdexamfetamine—Agitation—Doxorubicin—kidney cancer	0.000711	0.000745	CcSEcCtD
Lisdexamfetamine—Nausea—Paclitaxel—kidney cancer	0.000709	0.000743	CcSEcCtD
Lisdexamfetamine—Asthenia—Capecitabine—kidney cancer	0.000703	0.000736	CcSEcCtD
Lisdexamfetamine—Palpitations—Doxorubicin—kidney cancer	0.000684	0.000716	CcSEcCtD
Lisdexamfetamine—Convulsion—Doxorubicin—kidney cancer	0.00067	0.000702	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Capecitabine—kidney cancer	0.00067	0.000702	CcSEcCtD
Lisdexamfetamine—Hypertension—Doxorubicin—kidney cancer	0.000668	0.0007	CcSEcCtD
Lisdexamfetamine—ADRA1B—AMPK Signaling—EEF2—kidney cancer	0.000661	0.0187	CbGpPWpGaD
Lisdexamfetamine—Anxiety—Doxorubicin—kidney cancer	0.000656	0.000688	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000654	0.000685	CcSEcCtD
Lisdexamfetamine—Dizziness—Capecitabine—kidney cancer	0.000648	0.000679	CcSEcCtD
Lisdexamfetamine—Dry mouth—Doxorubicin—kidney cancer	0.000644	0.000675	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Doxorubicin—kidney cancer	0.000631	0.000662	CcSEcCtD
Lisdexamfetamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.000626	0.0177	CbGpPWpGaD
Lisdexamfetamine—Vomiting—Capecitabine—kidney cancer	0.000623	0.000653	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Doxorubicin—kidney cancer	0.000619	0.000649	CcSEcCtD
Lisdexamfetamine—Rash—Capecitabine—kidney cancer	0.000618	0.000647	CcSEcCtD
Lisdexamfetamine—Dermatitis—Capecitabine—kidney cancer	0.000617	0.000647	CcSEcCtD
Lisdexamfetamine—Tachycardia—Doxorubicin—kidney cancer	0.000616	0.000646	CcSEcCtD
Lisdexamfetamine—Headache—Capecitabine—kidney cancer	0.000614	0.000643	CcSEcCtD
Lisdexamfetamine—Skin disorder—Doxorubicin—kidney cancer	0.000613	0.000643	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Doxorubicin—kidney cancer	0.00061	0.00064	CcSEcCtD
Lisdexamfetamine—Anorexia—Doxorubicin—kidney cancer	0.000602	0.000631	CcSEcCtD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—RYR1—kidney cancer	0.000596	0.0169	CbGpPWpGaD
Lisdexamfetamine—Nausea—Capecitabine—kidney cancer	0.000582	0.00061	CcSEcCtD
Lisdexamfetamine—Insomnia—Doxorubicin—kidney cancer	0.000571	0.000598	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Doxorubicin—kidney cancer	0.000563	0.00059	CcSEcCtD
Lisdexamfetamine—Somnolence—Doxorubicin—kidney cancer	0.000561	0.000588	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Doxorubicin—kidney cancer	0.000556	0.000582	CcSEcCtD
Lisdexamfetamine—SLC6A3—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC5A3—kidney cancer	0.000554	0.0157	CbGpPWpGaD
Lisdexamfetamine—Decreased appetite—Doxorubicin—kidney cancer	0.000549	0.000575	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000545	0.000571	CcSEcCtD
Lisdexamfetamine—Fatigue—Doxorubicin—kidney cancer	0.000544	0.00057	CcSEcCtD
Lisdexamfetamine—Constipation—Doxorubicin—kidney cancer	0.00054	0.000566	CcSEcCtD
Lisdexamfetamine—Urticaria—Doxorubicin—kidney cancer	0.000502	0.000526	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Doxorubicin—kidney cancer	0.000499	0.000523	CcSEcCtD
Lisdexamfetamine—SLC6A2—Monoamine Transport—TSC2—kidney cancer	0.000499	0.0141	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—AKAP13—kidney cancer	0.000469	0.0133	CbGpPWpGaD
Lisdexamfetamine—Hypersensitivity—Doxorubicin—kidney cancer	0.000465	0.000487	CcSEcCtD
Lisdexamfetamine—Asthenia—Doxorubicin—kidney cancer	0.000453	0.000475	CcSEcCtD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC5A3—kidney cancer	0.000451	0.0128	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Monoamine Transport—TSC2—kidney cancer	0.000442	0.0125	CbGpPWpGaD
Lisdexamfetamine—Diarrhoea—Doxorubicin—kidney cancer	0.000432	0.000453	CcSEcCtD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000423	0.012	CbGpPWpGaD
Lisdexamfetamine—Dizziness—Doxorubicin—kidney cancer	0.000418	0.000438	CcSEcCtD
Lisdexamfetamine—Vomiting—Doxorubicin—kidney cancer	0.000401	0.000421	CcSEcCtD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC5A3—kidney cancer	0.0004	0.0113	CbGpPWpGaD
Lisdexamfetamine—Rash—Doxorubicin—kidney cancer	0.000398	0.000417	CcSEcCtD
Lisdexamfetamine—Dermatitis—Doxorubicin—kidney cancer	0.000398	0.000417	CcSEcCtD
Lisdexamfetamine—Headache—Doxorubicin—kidney cancer	0.000396	0.000415	CcSEcCtD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—GJB1—kidney cancer	0.000395	0.0112	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—KEAP1—kidney cancer	0.000394	0.0112	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—EIF4EBP1—kidney cancer	0.000384	0.0109	CbGpPWpGaD
Lisdexamfetamine—Nausea—Doxorubicin—kidney cancer	0.000375	0.000393	CcSEcCtD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000374	0.0106	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TSC1—kidney cancer	0.000357	0.0101	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—KEAP1—kidney cancer	0.000349	0.0099	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—KCNMA1—kidney cancer	0.000331	0.00938	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—ACHE—kidney cancer	0.00032	0.00906	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000284	0.00806	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—BCHE—kidney cancer	0.000278	0.00789	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A3—kidney cancer	0.000252	0.00714	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000252	0.00713	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—ACHE—kidney cancer	0.000245	0.00694	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC5A5—kidney cancer	0.000238	0.00675	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Calcium Regulation in the Cardiac Cell—ITPR2—kidney cancer	0.00023	0.00653	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—SLC2A1—kidney cancer	0.00023	0.00651	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000223	0.00632	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—RYR1—kidney cancer	0.000223	0.00632	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000215	0.0061	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000215	0.00609	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000215	0.00609	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000215	0.00609	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—EGR1—kidney cancer	0.000213	0.00605	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—BCHE—kidney cancer	0.000213	0.00605	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC5A5—kidney cancer	0.000211	0.00598	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TSC2—kidney cancer	0.000208	0.0059	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—SLC2A1—kidney cancer	0.000204	0.00577	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—KCNMA1—kidney cancer	0.000197	0.00559	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—ITPR2—kidney cancer	0.000192	0.00544	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTP1—kidney cancer	0.000192	0.00543	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—ACHE—kidney cancer	0.00019	0.0054	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—EGR1—kidney cancer	0.000189	0.00536	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—NRF2 pathway—GSTM1—kidney cancer	0.000176	0.00499	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—ITPR2—kidney cancer	0.000172	0.00487	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTP1—kidney cancer	0.00017	0.00481	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—BCHE—kidney cancer	0.000166	0.0047	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—ANXA1—kidney cancer	0.000161	0.00456	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—NRF2 pathway—GSTM1—kidney cancer	0.000156	0.00442	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—OR4C13—kidney cancer	0.000155	0.00439	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—RELA—kidney cancer	0.000153	0.00432	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.00015	0.00425	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—ACHE—kidney cancer	0.000146	0.00414	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000145	0.00411	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000145	0.0041	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000145	0.0041	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000145	0.0041	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—kidney cancer	0.000144	0.00408	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—BRAF—kidney cancer	0.000142	0.00403	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—MTOR—kidney cancer	0.000141	0.00399	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—OR4C13—kidney cancer	0.000141	0.00399	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—LPA receptor mediated events—JUN—kidney cancer	0.000134	0.00379	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—kidney cancer	0.000133	0.00377	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—SLC-mediated transmembrane transport—SLC2A1—kidney cancer	0.000128	0.00364	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ATP7B—kidney cancer	0.000128	0.00363	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A3—kidney cancer	0.000128	0.00363	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ANXA2—kidney cancer	0.000128	0.00363	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—BCHE—kidney cancer	0.000127	0.0036	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—RAF1—kidney cancer	0.000119	0.00336	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	0.000113	0.00321	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	0.000109	0.0031	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—BRAF—kidney cancer	0.000109	0.00309	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—ANXA1—kidney cancer	0.000107	0.00302	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—RAF1—kidney cancer	9.09e-05	0.00258	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—ABCB1—kidney cancer	8.64e-05	0.00245	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—PIK3CA—kidney cancer	8.59e-05	0.00243	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—BRAF—kidney cancer	8.47e-05	0.0024	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—OR4C13—kidney cancer	8.31e-05	0.00236	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—AMPK Signaling—TP53—kidney cancer	8.31e-05	0.00235	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmission across Chemical Synapses—MAPK1—kidney cancer	8.13e-05	0.00231	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—ANXA1—kidney cancer	8.11e-05	0.0023	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (12/13) signalling events—PIK3CA—kidney cancer	8.03e-05	0.00228	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—kidney cancer	7.62e-05	0.00216	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—SLC2A1—kidney cancer	7.36e-05	0.00209	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—RAF1—kidney cancer	7.07e-05	0.002	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—LATS1—kidney cancer	7.07e-05	0.002	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—kidney cancer	6.75e-05	0.00191	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—SLC2A1—kidney cancer	6.52e-05	0.00185	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—BRAF—kidney cancer	6.49e-05	0.00184	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—AKAP13—kidney cancer	6.43e-05	0.00182	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Neuronal System—MAPK1—kidney cancer	6.23e-05	0.00177	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AMER1—kidney cancer	6.01e-05	0.0017	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—AKAP13—kidney cancer	5.84e-05	0.00166	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—kidney cancer	5.81e-05	0.00165	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—ABCB1—kidney cancer	5.81e-05	0.00165	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ITPR2—kidney cancer	5.47e-05	0.00155	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—RAF1—kidney cancer	5.42e-05	0.00154	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—POMC—kidney cancer	5.22e-05	0.00148	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—ABCB1—kidney cancer	5.15e-05	0.00146	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GPC3—kidney cancer	5.04e-05	0.00143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CER1—kidney cancer	5.04e-05	0.00143	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ITPR2—kidney cancer	4.97e-05	0.00141	CbGpPWpGaD
Lisdexamfetamine—SLC18A2—Transmembrane transport of small molecules—RAF1—kidney cancer	4.89e-05	0.00138	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmission across Chemical Synapses—MAPK1—kidney cancer	4.85e-05	0.00137	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—ANXA1—kidney cancer	4.58e-05	0.0013	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—SFRP2—kidney cancer	4.28e-05	0.00121	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—kidney cancer	4.19e-05	0.00119	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—ANXA1—kidney cancer	4.16e-05	0.00118	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—kidney cancer	3.99e-05	0.00113	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR ligand binding—POMC—kidney cancer	3.97e-05	0.00113	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—G alpha (q) signalling events—PIK3CA—kidney cancer	3.87e-05	0.0011	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—kidney cancer	3.77e-05	0.00107	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Neuronal System—MAPK1—kidney cancer	3.72e-05	0.00105	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—kidney cancer	3.46e-05	0.000981	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CASP2—kidney cancer	3.45e-05	0.000978	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—AKAP13—kidney cancer	3.45e-05	0.000978	CbGpPWpGaD
Lisdexamfetamine—SLC6A2—Transmembrane transport of small molecules—RAF1—kidney cancer	3.29e-05	0.000932	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—GRB7—kidney cancer	3.16e-05	0.000895	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ITPR2—kidney cancer	2.93e-05	0.000832	CbGpPWpGaD
Lisdexamfetamine—SLC6A3—Transmembrane transport of small molecules—RAF1—kidney cancer	2.91e-05	0.000826	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CTNNA1—kidney cancer	2.66e-05	0.000754	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HSPB1—kidney cancer	2.65e-05	0.00075	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—EIF4EBP1—kidney cancer	2.65e-05	0.00075	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PSMD7—kidney cancer	2.46e-05	0.000697	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TSC1—kidney cancer	2.46e-05	0.000697	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ANXA1—kidney cancer	2.46e-05	0.000697	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—FLT1—kidney cancer	2.38e-05	0.000675	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—POMC—kidney cancer	2.25e-05	0.000637	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PAK1—kidney cancer	2.21e-05	0.000626	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JUNB—kidney cancer	2.21e-05	0.000626	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—POMC—kidney cancer	2.04e-05	0.000578	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF2—kidney cancer	1.81e-05	0.000512	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN2B—kidney cancer	1.8e-05	0.000509	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IGF1R—kidney cancer	1.75e-05	0.000495	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—RAF1—kidney cancer	1.68e-05	0.000477	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—IL2—kidney cancer	1.66e-05	0.000471	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—IL2—kidney cancer	1.51e-05	0.000427	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—HIF1A—kidney cancer	1.44e-05	0.000407	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TSC2—kidney cancer	1.43e-05	0.000406	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KDR—kidney cancer	1.37e-05	0.00039	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KIT—kidney cancer	1.27e-05	0.000359	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—APC—kidney cancer	1.27e-05	0.000359	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAPK3—kidney cancer	1.21e-05	0.000344	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—POMC—kidney cancer	1.2e-05	0.000342	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—BRAF—kidney cancer	1.19e-05	0.000337	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—MAPK1—kidney cancer	1.15e-05	0.000327	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—GPCR downstream signaling—PIK3CA—kidney cancer	1.1e-05	0.000312	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—KRAS—kidney cancer	1.09e-05	0.000309	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling by GPCR—PIK3CA—kidney cancer	1e-05	0.000284	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RAF1—kidney cancer	9.93e-06	0.000282	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—RELA—kidney cancer	9.89e-06	0.00028	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—ERBB2—kidney cancer	9.83e-06	0.000279	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MTOR—kidney cancer	9.7e-06	0.000275	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CDKN1B—kidney cancer	9.1e-06	0.000258	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—IL2—kidney cancer	8.91e-06	0.000253	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CCND1—kidney cancer	8.68e-06	0.000246	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—JUN—kidney cancer	8.67e-06	0.000246	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	8.6e-06	0.000244	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PTEN—kidney cancer	8.38e-06	0.000238	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	7.57e-06	0.000215	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	7.16e-06	0.000203	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MYC—kidney cancer	6.97e-06	0.000197	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	6.81e-06	0.000193	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—KRAS—kidney cancer	6.44e-06	0.000182	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	5.91e-06	0.000168	CbGpPWpGaD
Lisdexamfetamine—ADRA1B—Signaling Pathways—TP53—kidney cancer	5.72e-06	0.000162	CbGpPWpGaD
